Antibody Humanization and Affinity Maturation Services and Platforms Markets, 2017-2030

News provided by

Research and Markets

28 Sep, 2017, 11:45 GMT

DUBLIN, September 28, 2017 /PRNewswire/ --

The "Antibody Humanization and Affinity Maturation: Services and Platforms, 2017-2030" report has been added to Research and Markets' offering.

The "Antibody Humanization and Affinity Maturation: Services and Platforms, 2017-2030" report provides a comprehensive view on the current landscape and the future outlook of the antibody humanization and affinity maturation contract research services and platforms market. The study presents an in-depth analysis of a diverse set of companies that provide such services across different regions worldwide.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as number of projects being out-sourced, number of projects undertaken per year and expected pricing, we have provided an informed estimate of the likely evolution of the opportunity for antibody humanization and affinity maturation services providers for the period 2017-2030. The base year for the report is 2017. To account for the uncertainties associated with these services and to add robustness to our model, we have provided three forecast scenarios portraying conservative, base and optimistic tracks of the market's evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. The opinions and insights presented in this study were also influenced by discussions conducted with experts in this field. These included contributions from Aaron Sato (CSO of LakePharma), Andrew C.R. Martin (Reader in Bioinformatics and Computational Biology at University College London) and Thomas Schirrmann (General Manager of YuMab).

Key Topics Covered:

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Antibody: Historical Background
3.3. Antibody: Structure
3.4. Antibody: Mechanism of Action
3.5. Polyclonal and Monoclonal Antibodies
3.6. Bispecific Antibodies
3.7. Monoclonal Antibodies: A Rapidly Growing Industry
3.7.1. Monoclonal Antibodies: Hurdles and Challenges
3.7.2. Monoclonal Antibodies: Immunogenicity
3.7.2.1. Rational Approaches
3.7.2.1.1. Chimerization
3.7.2.1.2. CDR-Grafting
3.7.2.1.3. Resurfacing
3.7.2.1.4. Superhumanization
3.7.2.1.5. Human String Content Optimization
3.7.2.2. Non-Rational or Empirical Approaches
3.7.2.2.1. Framework Region Library
3.7.2.2.2. Guided Selection
3.7.2.2.3. Framework Region Shuffling
3.7.2.3. Other Methods
3.7.2.3.1. Shotgun Mutagenesis
3.7.2.3.2. Transgenic Animals
3.7.2.4. Monoclonal Antibodies: From Murine to Human
3.7.3. Monoclonal Antibodies: Affinity and Affinity Maturation
3.7.3.1. In Vivo Affinity Maturation
3.7.3.2. In Vitro Affinity Maturation
3.7.3.2.1. Display Technologies
3.7.3.2.2. Other Methods
3.8. Monoclonal Antibodies: Key Enablers
3.9. Monoclonal Antibodies: The Future

4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Antibody Humanization and Affinity Maturation Services and Platforms Providers: Market Landscape
4.2.1. Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Specialization
4.2.2. Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Type of Offering
4.2.3. Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Year of Establishment and Specialization
4.2.4. Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Humanization Method Used
4.2.5. Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Affinity Maturation Method Used
4.2.6. Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Drug Discovery Expertise
4.2.7. Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Geographical Location
4.2.8. Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Source Animal
4.2.9. Antibody Humanization and Affinity Maturation Services and Platforms Providers: Distribution by Business Model
4.3. Antibody Humanization and Affinity Maturation Services and Platforms Market: Key Insights
4.3.1. Outsourcing is More Prevalent as Compared to In-house Development
4.3.2. Flexible Service Models are Likely to Attract Drug Developers
4.3.3. Despite the Rise of Fully Human Antibody Generating Platform, the Low Fees and Emergence of Novel Humanization Techniques is Likely to Sustain Interest in this Domain
4.3.4. Humanization and Affinity Maturation Services are Potential Opportunities for Antibody Discovery Services Providers

5. COMPANY PROFILES: SERVICES AND PLATFORMS PROVIDERS

6. COMPANY PROFILES: OTHER ACTIVE PLAYERS

7. BENCHMARK ANALYSIS
7.1. Chapter Overview
7.2. Benchmark Analysis: Methodology
7.3. Benchmark Analysis: Peer Groups
7.3.1. Benchmark Analysis: North America, Peer Group I
7.3.2. Benchmark Analysis: North America, Peer Group II
7.3.3. Benchmark Analysis: North America, Peer Group III
7.3.4. Benchmark Analysis: Europe, Peer Group IV
7.3.5. Benchmark Analysis: Europe, Peer Group V
7.3.6. Benchmark Analysis: Europe, Peer Group VI
7.3.7. Benchmark Analysis: Asia Pacific, Peer Group VII
7.3.8. Benchmark Analysis: Asia Pacific, Peer Group VIII

8. PUBLICATION ANALYSIS
8.1. Chapter Overview
8.2. Antibody Humanization: Publications
8.2.1. Publication Analysis: Year-wise Trend
8.2.2. Publication Analysis: Key Journals
8.2.3. Publication Analysis: Distribution by Animal Models Used
8.2.4. Publication Analysis: Distribution by Method Used for Humanization

9. SWOT ANALYSIS

10. MARKET FORECAST
10.1. Chapter Overview
10.2. Forecast Methodology
10.3. Antibody Humanization and Affinity Maturation Services Market, 2017-2030
10.4. Antibody Humanization and Affinity Maturation Services Market, 2017-2030: Distribution by Number of Projects
10.5. Antibody Humanization and Affinity Maturation Services Market, 2017-2030: Distribution by Location of Services Providers
10.6. Antibody Humanization and Affinity Maturation Services Market, 2017-2030: Geographical Distribution by Demand
10.7. Antibody Humanization and Affinity Maturation Services Market, 2017-2030: Balance of Trade Analysis

11. GUIDE TO OUTSOURCING
11.1. Chapter Overview
11.2. Out-sourcing: The Growing Need
11.3. Out-sourcing: Matrix of Services
11.4. Out-sourcing: The Decision Making Criteria
11.4.1. Cost vs Peripheral Activity Model
11.4.1.1. Case Study I
11.4.2. Transaction Cost Economics Model
11.4.2.1. Case Study II
11.4.3. Cost Assessment Model
11.4.3.1. Case Study III
11.4.4. Out-Sourcing: Decision Tree
11.4.5. Out-Sourcing: Key Parameters for Choosing a Service Provider

12. CONCLUSION
12.1. Owing to the Growing Demand for Monoclonal Antibodies, Antibody Discovery Services Providers Have Garnered Significant Interest from Drug Developers
12.2. Despite the Availability of Fully Human Antibody Generating Platforms, the Opportunity for Antibody Humanization Services Providers Remains Largely Unaffected
12.3. CDR-Grafting is the Most Prominent Method for Antibody Humanization; Services Providers are Regularly Improving to Further Enhance the Technique
12.4. North America Spearheads the Market with the Largest Number of Antibody Humanization and Affinity Maturation Services Providers
12.5. Advances in Manufacturing Tools, Availability of Robust Technical Data, and Novel Business Models Indicate Potential Future Growth Opportunities
12.6. Given the Growing Demand for Antibody-based Products, the Contract Services Market is Anticipated to Witness Steady Growth in the Coming Decade
12.7. Concluding Remarks

13. INTERVIEW TRANSCRIPTS
13.1. Aaron Sato, Chief Scientific Officer, LakePharma
13.2. Andrew C.R. Martin, Reader in Bioinformatics and Computational Biology, University College London
13.3. Thomas Schirrmann, General Manager, YUMAB

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

  • Ab Studio
  • A&G Pharmaceutical
  • Abbott
  • AbbVie
  • Abcam
  • AbCheck
  • Absolute Antibody
  • Abwiz Bio
  • Abzena
  • Abzyme Therapeutics
  • Accurus Biosciences
  • ACROBiosystems
  • Affimed
  • AIMM Therapeutics
  • Akeso Biopharma
  • Alder BioPharmaceuticals
  • Alexion Pharmaceuticals
  • Amgen
  • AnaptysBio
  • Apexigen
  • Aragen Bioscience
  • Aristi Biotech
  • AstraZeneca
  • ATUM
  • AvantGen
  • AxioMx
  • Biogen
  • Bio-Rad
  • BIOTEM
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • CAPRA Science Antibodies
  • CARsgen Therapeutics
  • Chugai Pharmaceuticals
  • CisbioCorixa
  • Creative Biolabs
  • Cytogen
  • DaTaMabs
  • Distributed bio
  • Elan Pharma
  • Eli Lilly
  • Elusys Therapeutics
  • ExonBIO
  • Fresenius
  • Fusion Antibodies
  • G&P Biosciences
  • GeneBeyond
  • Genentech
  • Genmab
  • GenScript
  • Genzyme
  • GlaxoSmithKline
  • GlycoNex
  • Henlix Biotech
  • Human Genome Sciences
  • iDD biotech
  • ImClone Systems
  • Immune Biosolutions
  • Immunomedics
  • ImmunoPrecise Antibodies
  • Innate Pharma
  • Innovative Targeting Solutions
  • Integral Molecular
  • IONTAS
  • Janssen Biotech
  • Johnson & Johnson
  • LakePharma
  • Lonza
  • MabPlex
  • MabSpace Biosciences
  • Macromoltek
  • MedImmune
  • Merck
  • MIGS
  • Millennium Pharmaceuticals
  • Mi-mAbs
  • ModiQuest Research
  • Morphotek
  • MRC Technology (LifeArc)
  • NeoRx
  • Noble Life Sciences
  • Novartis
  • Oak Biosciences
  • Organon Teknika
  • Palatin Technologies
  • Panorama Research
  • Pharmaron
  • Precision Antibody
  • ProteoGenix
  • PX'Therapeutics
  • QoolAbs
  • Regeneron Pharmaceuticals
  • Roche
  • Rx Biosciences
  • Sanofi
  • Seattle Genetics
  • Sino Biological
  • Specifica
  • STC Biologics
  • Syd Labs
  • Takeda Pharmaceutical
  • Teva Pharmaceutical
  • Union Chimique Belge
  • United Therapeutics
  • University of Virginia School of Medicine
  • Valeant Pharmaceuticals
  • Viva Biotech
  • Viventia Bio
  • Vrisko
  • WuXi Biologics
  • Wyeth
  • XOMA
  • YUMAB
  • Yurogen Biosystems
  • Zymeworks

For more information about this report visit https://www.researchandmarkets.com/research/h8dsxn/antibody

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716